There is deterioration of the quality of life of those with IgAN

Without effective management of IgA Nephropathy, it can have negative effects on the emotional and psychosocial aspects of the life of those affected.1 In addition, the symptoms and the side effects of medication limit the capacity of IgA Nephropathy patients to participate in activities that are important to them, such as sport and social interaction.1

Moreover, the mortality rate of individuals with moderate to high grade IgA Nephropathy is higher by a factor of two. In a large-scale cohort study (N=665) that was conducted over a mean duration of 11.8 years (actual duration: 0.0-20.8 years), the IgA Nephropathy death rate among patients was found to be twice as high as that among the general population.2 

The progression of IgA Nephropathy can have significant negative impacts on the future plans of those affected.


of those who require haemodialysis find that this has consequences for their careers or education.3


of all those affected find that they need to completely revise their plans for the future.3

When a particular stage of renal failure is reached in which haemodialysis becomes necessary, this can have very negative consequences for the quality of life of the individual concerned.3


~ 50 %

suffer from insomnia.3


< 40 %

frequently or very frequently feel fatigued.3

decreased appetite

~ 15 %

frequently or very frequently suffer from loss of appetite.3

Problems with the sex life of patients


frequently or very frequently experience problems with their sex life.3

* *The above statistics are for haemodialysis patients who reported these symptoms occurring “frequently” or “very frequently” in a survey based on the modified KDQOL-SF 1.2 questionnaire.

Learn more about IgAN

What is IgAN?

What is IgAN?

Gain initial insights into IgA Nephropathy, its main symptoms, its progression and its effects on the kidneys. You will be surprised at the complexity of the disease!

Causes of IgA Nephropathy

Causes of IgA Nephropathy

Learn about the pathogenesis of IgA Nephropathy : Learn how IgAN has its origin in the gut, the role played by the peyer’s patches and IgA in the development of the disease and what causative factors there are. 

The treatment gap

The treatment gap

How has IgA Nephropathy been treated to date and what are the complications associated with medical intervention? Click here to learn more about the risk/benefit profile of currently available treatment options


  1.  IgA Nephropathy Foundation of America, Inc. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy, under: accessed: February 2022).
  2. Knoop T et al. Mortality in patients with IgA Nephropathy. Am J Kidney Dis 2013; 62(5): 883–890. 
  3. Dabrowska-Bender M et al. The impact on quality of life of dialysis patients with renal insufficiency. Patient Prefer Adherence 2018; 12: 577–583.